Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase ...

SAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Related Keywords

Israel ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Shanghai ,China ,United States ,Boston ,Massachusetts ,Germany ,American ,Joyce Allaire ,Scottl Friedman ,Sagimet Biosciences ,Moshe Oren ,Alpha Omega Honor Society ,Weizmann Institute Of Science ,International Hans Popper Award ,Exchange Commission ,Harvard Medical School ,American Liver Foundation ,American College Of Physicians ,Falk Foundation In Freiburg ,Sagimet Biosciences Inc ,American Gastroenterological Association ,American Association For The Advancement Science ,Division Of Liver Diseases ,Icahn School Of Medicine At Mount Sinai ,Division Of Liver Diseases At Mount Sinai ,Nasdaq ,Icahn School ,Mount Sinai ,Therapeutic Discovery ,Liver Diseases ,Medical Resident ,Beth Israel Hospital ,Gastroenterology Fellowship ,Senior Fulbright Scholar ,Visiting Professor ,Weizmann Institute ,Professor Moshe ,Falk Foundation ,European Association ,Liver Diseases International Recognition Award ,Shanghai Magnolia Gold Award ,China Friendship Award ,Distinguished Achievement Awards ,American Liver ,American College ,American Association ,Private Securities Litigation Reform Act ,